Differential power of placebo across major psychiatric disorders: a preliminary meta-analysis and machine learning study

• Autor(a) principal: Cao, Bo
• Data de Publicação: 2021
• Outros Autores: Liu, Yang S., Selvitella, Alessandro, Garcia, Diego Librenza, Passos, Ives Cavalcante, Sawalha, Jeffrey, Ballester, Pedro Lemos, Chen, Jianhang, Dong, Shimiao, Wang, Fei, Kapczinski, Flávio Pereira, Dursun, Serdar, Li, Xin-Min, Greiner, Russell, Greenshaw, Andrew
• Tipo de documento: Artigo
• Idioma: eng
• Título da fonte: Repositório Institucional da UFRGS
• Texto Completo: http://hdl.handle.net/10183/245614
• topic: Placebos; Transtornos mentais; Revisão sistemática; Metanálise; Aprendizado de máquina

The placebo effect across psychiatric disorders is still not well understood. In the present study, we conducted meta-analyses including meta-regression, and machine learning analyses to investigate whether the power of placebo effect depends on the types of psychiatric disorders. We included 108 clinical trials (32,035 participants) investigating pharmacological intervention effects on major depressive disorder (MDD), bipolar disorder (BD) and schizophrenia (SCZ). We developed measures based on clinical rating scales and Clinical Global Impression scores to compare placebo effects across these disorders. We performed meta-analysis including meta-regression using sample-size weighted bootstrapping techniques, and machine learning analysis to identify the disorder type included in a trial based on the placebo response. Consistently through multiple measures and analyses, we found differential placebo effects across the three disorders, and found lower placebo effect in SCZ compared to mood disorders. The differential placebo effects could also distinguish the condition involved in each trial between SCZ and mood disorders with machine learning. Our study indicates differential placebo effect across MDD, BD, and SCZ, which is important for future neurobiological studies of placebo effects across psychiatric disorders and may lead to potential therapeutic applications of placebo on disorders more responsive to placebo compared to other conditions.